Key points are not available for this paper at this time.
BACKGROUND: To understand the clinical outcomes of selenium therapy in patients with sepsis syndrome, we conducted a meta-analysis of randomized controlled trials (RCT). METHODS: A total of 13 RCTs comparing selenium and placebo for patients with sepsis were reviewed systematically. RESULTS: However, we could not detect the association of selenium treatment with a decreased mortality at different time course (relative risk RR 95% confidence interval, CI: 0.94 0.82-1.06 at day 28; 0.73 0.36-1.47 at day 90; 1.16 0.78-1.71 at 6 months; respectively). Selenium supplementation did not show favorable efficacy in the incidence of renal failure, secondary infection or duration of mechanical ventilation (RR 95% CI: 0.65 0.41-1.03; 0.96 0.87-1.06; standard mean difference SMD 95% CI: 0.17 -0.30-0.63; respectively). Interestingly, we found that selenium therapy was benefit for sepsis patients with reduced duration of vasopressor therapy, staying time in intensive care unit and hospital, and incidence of ventilator-associated pneumonia (SMD 95% CI: -0.75 -1.37 to -0.13; -0.15 CI: -0.25 to -0.04; -1.22 -2.44 to -0.01; RR 95% CI: 0.61 0.42-0.89; respectively). CONCLUSION: Based on our findings, intravenous selenium supplementation could not be suggested for routine use.
Li et al. (Thu,) studied this question.